Market Cap
$4.2B
INDV
Indivior Pharmaceuticals, Inc.
$35.69 ▲ +0.88%
Prev close $35.38Market cap$4.2B
ConsensusStrong Buy
12-mo target$49.00 (+37.3%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)31 New Institutional Positions19 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on INDV right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (90%)
Inst. Holders
50 funds
Inst. Value
$3.6B
Inst. Activity
31 buys / 19 sells
Insider Activity
$139.2K buy / $2.8M sell
Insider Net $
-$2.7M
SEC Reports
16
Press Releases
2
Price chart 30d +1.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 short_volume
Short Volume: INDV — 86.0% short (0.5M / 0.5M)
Short: 453,808 | Exempt: 20 | TRF Vol: 527,651 | Short Ratio: 86.0% | Off-exchange volume (dark pool
Sep 22, 2026 Event
Sep 14, 2026 SEC HSR Early Termination: Indivior Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Indivior
Indivior Pharmaceuticals' S-4 registration statement (File No. 333-298637) was declared effective by the SEC on Septembe
EFFECT — Impact 4/10
Indivior Pharmaceuticals filed an S-4 registration statement for an all-stock merger of equals with Supernus Pharmaceuti
S-4 — Impact 6/10
Aug 27, 2026 Insider
Anderson Woodrow D bought 1,500 shares
Chief Accounting Officer @ $35.69 ($53.5K)
Aug 5, 2026 Insider
Aug 3, 2026 SEC Anderson Woodrow D bought 1,500 shares
Chief Accounting Officer @ $36.28 ($54.4K)
Indivior announces transformative all-stock merger of equals with Supernus Pharmaceuticals. Each Supernus share will con
425, 8-K — Impact 7/10
Jul 27, 2026 Event
SUBLOCADE
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AN
Analyst ratings buy % -2.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
90% rate it Buy or better · 10 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 5, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Jun 18, 2026 | Barclays | INITIATE | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Aug 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% |
Price targets
Where 4 covering analysts think INDV trades over the next 12 months.
$49.00 +37.3% upside Strong Buy
Current$35.69 Low$43.00 Median$50.00 High$53.00 4 analysts
$43.00$53.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 6 bullish, 0 bearish, 0 mixed, 10 neutral · avg impact 5.0/10.Plus 2 press releases.
NEUTRALEFFECT4/10
Indivior Pharmaceuticals' S-4 registration statement (File No. 333-298637) was declared effective by
Sep 14, 2026
NEUTRALS-46/10
Indivior Pharmaceuticals filed an S-4 registration statement for an all-stock merger of equals with
Aug 28, 2026
BULLISH425, 8-K7/10
Indivior announces transformative all-stock merger of equals with Supernus Pharmaceuticals. Each Sup
Aug 3, 2026
BULLISH8-K8/10
Indivior reported record Q2 2026 results with total net revenue of $343M (+14% YoY), record SUBLOCAD
Aug 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
short_volume
Short Volume: INDV — 86.0% short (0.5M / 0.5M)
Short: 453,808 | Exempt: 20 | TRF Vol: 527,651 | Short Ratio: 86.0% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: INDV — 63.7% short (0.3M / 0.5M)
Short: 338,148 | Exempt: 3 | TRF Vol: 531,060 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
Enforcement
HSR Early Termination: Indivior Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Indivior Pharmaceuticals, Inc.; Supernus Pharmaceuticals,
Sep 21, 2026
short_volume
Short Volume: INDV — 79.0% short (0.4M / 0.5M)
Short: 400,122 | Exempt: 0 | TRF Vol: 506,566 | Short Ratio: 79.0% | Off-exchange volume (dark pool + OTC)
Sep 18, 2026
short_volume
Short Volume: INDV — 88.4% short (0.9M / 1.0M)
Short: 876,877 | Exempt: 1,069 | TRF Vol: 991,940 | Short Ratio: 88.4% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.12 | $1.09–$1.15 | 55.4% | +15.3% | 2↑ 0↓ | $0.3B | 2 |
| Next Q | $1.21 | $1.21–$1.22 | 48.1% | +16.5% | 2↑ 0↓ | $0.3B | 2 |
| Current FY | $4.41 | $4.36–$4.47 | 76.3% | +15.3% | 3↑ 0↓ | $1.3B | 3 |
| Next FY | $4.88 | $4.74–$5.02 | 10.8% | +17.9% | 3↑ 0↓ | $1.4B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.119 | — |
| 7d ago | $0.981 | +0.138 |
| 30d ago | $0.971 | +0.148 |
| 60d ago | $0.990 | +0.129 |
| 90d ago | $0.990 | +0.129 |
Institutional ownership
Which big funds own INDV (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.6B total value (88,437,451 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, VANGUARD. Net buying activity: 31 institutions added/increased vs 19 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 18,709,432 | $767.6M | 21.2% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7,572,287 | $310.7M | 8.6% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,495,486 | $225.5M | 6.2% | — |
| STATE STREET CORP | 4,992,071 | $204.8M | 5.6% | — |
| FULLER & THALER ASSET MANAGEMENT, INC. | 4,615,816 | $189.4M | 5.2% | — |
| MORGAN STANLEY | 3,395,702 | $139.3M | 3.8% | — |
| FRANKLIN RESOURCES INC | 3,316,358 | $136.1M | 3.7% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 3,159,866 | $129.7M | 3.6% | — |
| CITADEL ADVISORS LLC | 2,667,827 | $109.5M | 3.0% | TRIM -25.4% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,299,054 | $94.3M | 2.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | TRIM | 3,574,044 | 2,667,827 | -25.4% | $109.5M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 4,595,535 | 2,098,945 | -54.3% | $86.1M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 1,332,128 | 1,896,605 | +42.4% | $77.8M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 2,323,264 | 1,642,086 | -29.3% | $67.4M |
| Assenagon Asset Management S.A. | NEW | — | 1,540,928 | — | $63.2M |
| Point72 Asset Management, L.P. | DOUBLED | 94,943 | 1,250,639 | +1217.3% | $51.3M |
| UBS Group AG | TRIM | 2,192,264 | 1,160,618 | -47.1% | $47.6M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | NEW | — | 1,041,191 | — | $42.7M |
| BARCLAYS PLC | TRIM | 1,745,751 | 907,024 | -48.0% | $37.2M |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | TRIM | 1,835,100 | 698,900 | -61.9% | $28.7M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 43 transactions. Net -$2.7M — $139.2K bought, $2.8M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | Anderson Woodrow D | Chief Accounting Officer | BUY | 1,500 | $35.69 | $53.5K |
| Aug 5, 2026 | Anderson Woodrow D | Chief Accounting Officer | BUY | 1,500 | $36.28 | $54.4K |
| Jul 10, 2026 | Heidbreder Christian | Chief Scientific Officer | SELL | 18,586 | $41.14 | $764.6K |
| Jun 22, 2026 | Ciaffoni Joseph | Chief Executive Officer | EXERCISE | 1,266,903 | — | — |
| Jun 22, 2026 | Ciaffoni Joseph | Chief Executive Officer | TAX W/H | 612,549 | $38.32 | $23.5M |
| Jun 11, 2026 | Heidbreder Christian | Chief Scientific Officer | SELL | 18,586 | $38.06 | $707.4K |
| Jun 8, 2026 | Preblick Ryan | Chief Financial Officer | SELL | 36,000 | $37.70 | $1.4M |
| May 13, 2026 | Wheadon David E. | Director | AWARD | 10,430 | — | — |
| May 13, 2026 | NINIVAGGI DANIEL A | Director | AWARD | 6,518 | — | — |
| May 13, 2026 | Ryan Barbara | Director | AWARD | 6,518 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for INDV.
Shares short
11,172,005
Settlement Sep 15, 2026
Change vs prior
-1.1%
Semi-monthly cycle
Days to cover
5.7
At avg daily volume
Of shares outstanding
≈9.5%
Estimate — not % of float
All INDV filing & press-release reports (18)
- EFFECT reportSep 14, 2026
- S-4 reportAug 28, 2026
- 425, 8-K reportAug 3, 2026
- 8-K reportAug 3, 2026
- 425 reportAug 3, 2026
- 425, 8-K reportAug 3, 2026
- PRESS-RELEASE reportJul 23, 2026
- CLUSTER reportJun 12, 2026
- 8-K reportMay 15, 2026
- 8-K reportMay 4, 2026
- 8-K reportApr 30, 2026
- PRESS-RELEASE reportApr 24, 2026
- PRESS-RELEASE reportApr 9, 2026
- CLUSTER reportMar 13, 2026
- 8-K reportMar 13, 2026
- PRESS-RELEASE reportMar 13, 2026
- 8-K reportMar 12, 2026
- 8-K reportFeb 26, 2026